Table 3 Clinical and laboratory measures for participants at baseline and 6 months. Data presented are arithmetic means (SDs) number (%), unless otherwise stated
Control (n = 66) | Intervention (n = 67) | Difference in mean changes in intervention group | ||||
|---|---|---|---|---|---|---|
Baseline Mean (SD) | 6 months Mean (SD) | Baseline Mean (SD) | 6 months Mean (SD) | Ratio (95% CI) | p-value | |
HbA1c (mmol/mol) | 43.0 (2.2) | 43.8 (6.2) | 43.2 (2.2) | 42.0 (3.6) | 0.96 (0.92, 1.00) | 0.096 |
Weight (kg)a | 93.7 (15.1) | 94.6 (15.5) | 96.9 (21.5) | 95.6 (23.8) | 0.97 (0.95, 0.98) | < 0.001 |
BMI (kg/m2)b | 33.0 (6.0) | 33.3 (6.1) | 35.1 (7.4) | 34.5 (8.1) | – | |
Waist circumference (cm) | 104.0 (17.9) | 106.0 (12.2) | 109.4 (15.2) | 107.7 (16.3) | 0.97 (0.94, 1.00) | 0.101 |
Systolic blood pressure (mmHg) | 132.7 (17.0) | 135.0 (16.8) | 133.0 (13.7) | 131.2 (13.8) | 0.97 (0.92, 1.05) | 0.422 |
Diastolic blood pressure (mmHg) | 81.2 (10.9) | 80.3 (10.7) | 79.6 (9.1) | 79.2 (9.2) | 1.00 (0.94, 1.04) | 0.949 |
Total cholesterol (mmol/l) | 5.3 (1.3) | 5.2 (1.3) | 5.3 (1.4) | 5.2 (1.1) | 1.00 (0.95 1.08) | 0.933 |
HDL-cholesterol (mmol/l) | 1.2 (0.3) | 1.2 (0.4) | 1.3 (0.5) | 1.3 (0.5) | 1.02 (0.96, 1.09) | 0.595 |
Triglycerides (mmol/l) | 2.4 (1.8) | 2.4 (1.7) | 2.1 (1.1) | 2.2 (1.3) | 0.95 (0.79, 1.24) | 0.596 |
Alanine transaminase (IU/L) | 33.7 (20.3) | 33.4 (18.2) | 28.5 (15.2) | 26.0 (12.3) | 0.91 (0.75, 1.03) | 0.206 |
Aspartate aminotransferase (IU/L) | 25.6 (10.3) | 25.6 (11.3) | 23.9 (7.5) | 22.9 (9.7) | 0.95 (0.73, 1.12) | 0.649 |
Gamma glutamyl transpeptidase (IU/L)c | 39.0 (31.5) | 41.0 (33.0) | 32.0 (61.0) | 31.0 (53.0) | −4.00 (−8.19, 2.22) | 0.369 |
Urate (mmol/l) | 0.39 (0.11) | 0.37 (0.09) | 0.36 (0.07) | 0.37 (0.08) | 0.02 (−0.01, 0.25) | 0.799 |